Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN), Cue Biopharma (CUE) and Guardant Health (GH)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Supernus Pharmaceuticals (SUPN – Research Report), Cue Biopharma (CUE – Research Report) and Guardant Health (GH – Research Report).

Supernus Pharmaceuticals (SUPN)

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Supernus Pharmaceuticals, with a price target of $46.00. The company’s shares closed last Tuesday at $36.18.

According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -2.6% and a 42.9% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

Currently, the analyst consensus on Supernus Pharmaceuticals is a Moderate Buy with an average price target of $45.50.

See the top stocks recommended by analysts >>

Cue Biopharma (CUE)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Cue Biopharma, with a price target of $7.00. The company’s shares closed last Tuesday at $4.85, close to its 52-week high of $5.04.

According to TipRanks.com, Tenthoff is a 5-star analyst with an average return of 17.1% and a 45.3% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Crispr Therapeutics AG, and Aslan Pharmaceuticals.

Currently, the analyst consensus on Cue Biopharma is a Strong Buy with an average price target of $10.00.

Guardant Health (GH)

Piper Sandler analyst David Westenberg maintained a Hold rating on Guardant Health today and set a price target of $35.00. The company’s shares closed last Tuesday at $23.99, close to its 52-week low of $20.67.

According to TipRanks.com, Westenberg is a 3-star analyst with an average return of 3.4% and a 48.6% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Elanco Animal Health, and Pacific Biosciences.

Guardant Health has an analyst consensus of Moderate Buy, with a price target consensus of $51.36.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SUPN:

• Supernus Announces First Quarter 2023 Financial Results
• SUPN Earnings this Week: How Will it Perform?
• Supernus to Present at the Bank of America 2023 Health Care Conference
• Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
• Supernus Announces Repayment of Convertible Notes